Investors

Investors

Corporate Profile

We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.

Stock Quote

Exchange
Price
Change (%)
Volume
Data as of
Exchange
Price
Change (%)
Volume
Data as of
More >>

Recent News

Date Title and Summary Additional Formats
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Dec. 11, 2017-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary Erytech Pharma: Monthly Information Related to Total Number of Voting Rights and Shares Composing the Share Capital –November 30, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France --(BUSINESS WIRE)--Dec. 11, 2017-- Regulatory News : Erytech Pharma (Euronext: ERYP- Nasdaq: ERYP): Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol : ERYP) &
View HTML
Toggle Summary ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France - December 8, 2017 - ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage
View HTML
Toggle Summary ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
Conference call and webcast to take place Monday, December 11th at 10:00 a.m. EST LYON, France --(BUSINESS WIRE)--Dec. 8, 2017-- Regulatory News : ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by
View HTML
More >>

Upcoming Events

Date Event Details
Summary Toggle Sep 9 - Sep 10, 2019

Morgan Stanley Global Healthcare Unplugged, New York

Summary Toggle Sep 17, 2019

Business Update and Financial Highlights for the 2nd quarter and first-half of 2019

Summary Toggle Sep 18, 2019 at 8:30 AM EDT

Erytech Pharma Second Quarter 2019 Conference Call and Webcast

RECEIVE E-MAIL ALERTS

Copyright West LLC. Minimum 15 minutes delayed.

Top